Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Sorensen

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
European Journal of Pharmacology|September 22, 1992
The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamineC J Schmidt, C K Black, V L Taylor, et al.
Psychopharmacology|January 1, 1993
Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic functionM G Palfreyman, C J Schmidt, S M Sorensen, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studiesS M Sorensen, J H Kehne, G M Fadayel, et al.
Molecular Pharmacology|October 1, 1990
Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding siteB M Baron, B L Harrison, F P Miller, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
European Journal of Pharmacology|September 22, 1992
The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamineC J Schmidt, C K Black, V L Taylor, et al.
Psychopharmacology|January 1, 1993
Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic functionM G Palfreyman, C J Schmidt, S M Sorensen, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 1, 1993
Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studiesS M Sorensen, J H Kehne, G M Fadayel, et al.
Molecular Pharmacology|October 1, 1990
Activity of 5,7-dichlorokynurenic acid, a potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding siteB M Baron, B L Harrison, F P Miller, et al.
Pageof 3